ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/vinca-alkaloid
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/vinca-alkaloid
22
trial(s) found.
NCT06960577
Curative
Phase 3
Recruiting
A Phase IIIb, Open-label, Single-arm, Global Study of Perioperative Durvalumab With Neoadjuvant ddMVAC or Gem/Cis in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) (
D933RC00002
)
anti-PD-L1 monoclonal antibody
+ vinca alkaloid
Bladder cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2109 - North Ryde - Macquarie University Hospital
2217 - Kogarah - St George Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NA
NA
NCT06564038
Haem
Phase 1 / Phase 2
Recruiting
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies (
Soundtrack-E
)
bispecific T-cell engager,CD19-targeting
+ vinca alkaloid
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Mantle cell lymphoma
Non-Hodgkin's lymphoma
Small lymphocytic lymphoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06459180
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (
2870-020
)
anti-Trop2 antibody-drug conjugate
+ vinca alkaloid
Cervical cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06435429
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment (
JZP598-303
)
anti-ERBB2 antibody-drug conjugate
anti-ERBB2 monoclonal antibody
bispecific ERBB2/ERBB2 antibody
+ vinca alkaloid
HER2-positive breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3149 - Mount Waverley - Waverley Private Hospital - Oncology
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06381570
Paed
Phase 0
Recruiting
VICTORY
: A Pilot Study to Investigate Safety and Efficacy of Weekly Combination of Intravenous Vinblastine With Oral Type II RAF Inhibitor Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas
RAF inhibitor,type 2
vinca alkaloid
Low-grade glioma
NCT06356129
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (
GOLSEEK-1
)
CELMoD agent
placebo
+ vinca alkaloid
Diffuse large B-cell lymphoma
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
QLD
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT06333899
Paed
Phase 1
Not yet recruiting
A Pilot Study of Lorlatinib for Treatment of Children With Newly Diagnosed High-Grade Glioma With ROS-1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase) or ALK (Anaplastic Lymphoma Kinase) Fusion (
TarGeT-L
)
ALK inhibitor,third generation
ROS1 inhibitor
+ vinca alkaloid
Anaplastic astrocytoma
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Glioblastoma
Glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05999994
Paed
Phase 2
Recruiting
CAMPFIRE
: Children's and Young Adult Master Protocol for Innovative Pediatric Research
Abemaciclib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Cyclophosphamide
Docetaxel
Gemcitabine
Irinotecan
Ramucirumab
Temozolomide
Vinorelbine
alkylating agent
anti-VEGFR2 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,VEGFR2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,VEGFR2-targeting
taxane
topoisomerase inhibitor
vinca alkaloid
+ vinca alkaloid
Cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Children's Hospital at Westmead
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT05605899
Haem
Phase 3
Recruiting
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (
ZUMA-23
)
autologous CAR-T-cell therapy,CD19-targeting
+ vinca alkaloid
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT05504291
Paed
Phase 2
Recruiting
Intravitreal Melphalan for Intraocular Retinoblastoma (
ARET2121
)
alkylating agent
+ vinca alkaloid
Retinoblastoma
WA
6009 - Perth - Perth Children's Hospital
NCT05359237
Paed
Recruiting
A Pharmacokinetic Study of VinCRIStine in Infants Dosed According to BSA-Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA Methods (
PEPN22P1
)
vinca alkaloid
Cancer
Lymphoma
Solid tumour
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT05304585
Paed
Phase 3
Recruiting
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma (
ARST2032
)
Cyclophosphamide
Dactinomycin
Radiotherapy
Vincristine
alkylating agent
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
vinca alkaloid
+ vinca alkaloid
Alveolar rhabdomyosarcoma
Embryonal rhabdomyosarcoma
Sclerosing rhabdomyosarcoma
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04884035
Paed
Phase 1
Recruiting
A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma (
CC-220-DLBCL-001
)
CELMoD agent
cereblon modulator
+ vinca alkaloid
Lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (COMPLETED)
WA
6000 - Perth - Royal Perth Hospital (COMPLETED)
NCT04625907
Radonc
Phase 1 / Phase 2
Recruiting
FaR-RMS
: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Cyclophosphamide
Dactinomycin
Doxorubicin
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
Ifosfamide
Irinotecan
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
PDGFR inhibitor
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
VEGFR inhibitor
Vincristine
Vinorelbine
alkylating agent
anthracycline
antineoplastic antibiotic
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cytotoxic chemotherapy
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
topoisomerase inhibitor
vinca alkaloid
+ vinca alkaloid
Rhabdomyosarcoma
NSW
2031 - Randwick - Sydney Children's Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Children's Hospital at Westmead
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04623541
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (
EPCORE™-CLL-1
)
bispecific T-cell engager,CD20-targeting
+ vinca alkaloid
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Small lymphocytic lymphoma
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
SA
5042 - Bedford Park - Flinders Medical Centre
NCT04332822
Haem
Phase 3
Recruiting
R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (
POLAR-BEAR
)
anti-CD79b antibody-drug conjugate
+ vinca alkaloid
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2487 - Cudgen - Tweed Valley Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3066 - Epping - Northern Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04221035
Radonc
Phase 3
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (
HR-NBL2
)
Busulfan
Carboplatin
Cisplatin
Cyclophosphamide
Dacarbazine
Dinutuximab
Doxorubicin
Etoposide
Ifosfamide
Irinotecan
Melphalan
Radiotherapy
Temozolomide
Thiotepa
Vincristine
alkylating agent
anthracycline
anti-GD2 monoclonal antibody
cancer therapy
cancer therapy,GD2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,GD2-targeting
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
+ vinca alkaloid
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
2305 - New Lambton Heights - John Hunter Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
WA
6009 - Perth - Perth Children's Hospital (SUSPENDED)
NCT03959085
Haem
Phase 3
Recruiting
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (
AALL1732
)
anti-CD22 antibody-drug conjugate
+ vinca alkaloid
Acute lymphoblastic leukaemia
B-cell acute lymphoblastic leukaemia/lymphoma
Leukaemia
Mixed phenotype acute leukaemia
NSW
2305 - New Lambton Heights - John Hunter Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (SUSPENDED)
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
ACTRN12624000532505
Radonc
Phase 3
Recruiting
International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1 (
INTER-EWING-1
)
Cyclophosphamide
Doxorubicin
Etoposide
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
Ifosfamide
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
PDGFR inhibitor
RET inhibitor
Radiotherapy
Regorafenib
VEGFR inhibitor
Vincristine
Vinorelbine
alkylating agent
anthracycline
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cytotoxic chemotherapy
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
topoisomerase inhibitor
vinca alkaloid
+ vinca alkaloid
Ewing sarcoma
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12621001529831
Haem
Phase 2
Recruiting
NHL35 -An Australasian Leukaemia and Lymphoma Group open label phase II study of the effect of of R-CHOP in combination with pembrolizumab in patients with newly diagnosed primary mediastinal B Cell Lymphoma (PMBL). (
PACIFIC
)
anti-PD-1 monoclonal antibody
+ vinca alkaloid
B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12619001656123
Haem
Phase 1
Not yet recruiting
Clarifying the role of early application of CAR T cells in Primary refractory and early relapsed diffuse large B cell lymphoma patients. (
CLARIFY-NHL34
)
Carboplatin
Cyclophosphamide
Doxorubicin
Etoposide
Fludarabine
Ifosfamide
Mesna
Prednisolone
Rituximab
Vincristine
alkylating agent
anthracycline
anti-CD20 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,CD20-targeting
cytotoxic chemotherapy
glucocorticoid
immuno-oncology therapy,CD20-targeting
platinum-based antineoplastic agent
sodium mercaptoethanesulfonate
topoisomerase inhibitor
vinca alkaloid
+ vinca alkaloid
Diffuse large B-cell lymphoma
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ vinca alkaloid
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (19)
Not yet recruiting (2)
Status unknown (1)
Recruitment Country and State
NSW (15)
VIC (13)
WA (12)
QLD (11)
NZ (5)
SA (4)
NT (1)
ACT (1)
TAS (1)
Phase
Phase 0 (1)
Phase 1 (3)
Phase 1 / Phase 2 (3)
Phase 2 (3)
Phase 3 (10)
Trial Type
Haem (8)
Paed (7)
Advanced (3)
Radonc (3)
Curative (1)
Cancer Therapy Class
CD20
36%
cereblon
14%
KIT
14%
PDGFR
14%
VEGFR
14%
PD-1/PD-L1
9%
BTK
9%
CD19
9%
CRAF
9%
RAF
9%
ALK
9%
ROS1
9%
CDK4
9%
CDK6
9%
CD79b
9%
FGFR
9%
FGFR1
9%
FGFR1/2/3
9%
FGFR2
9%
FGFR3
9%
FGFR4
9%
RET
9%
PD-L1
5%
TF
5%
Trop2
5%
ERBB2
5%
BRAF
5%
pan-RAF
5%
DPD
5%
orotate phosphoribosyltransferase
5%
VEGFR2
5%
Bcl2
5%
GD2
5%
CD22
5%
PD-1
5%
ATR
5%
BCR-ABL1
5%
EGFR
5%
FLT3
5%
JAK1
5%
JAK2
5%
MET
5%
PDGFRA
5%
PI3K
5%
SMO
5%
SRC
5%
YES1
5%
mTOR
5%
mTORC1
5%
mTORC2
5%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (6)
6009 - Perth - Perth Children's Hospital (6)
2050 - Camperdown - Chris O'Brien Lifehouse (6)
2145 - Westmead - The Children's Hospital at Westmead (5)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (4)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (4)
2031 - Randwick - Sydney Children's Hospital (4)
4101 - South Brisbane - Queensland Children's Hospital (4)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (3)
NZ.1023 - Grafton - Starship Children's Hospital (3)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (3)
2305 - New Lambton Heights - John Hunter Children's Hospital (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
2217 - Kogarah - St George Hospital (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (2)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (2)
3168 - Clayton - Monash Medical Centre (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
4215 - Southport - Gold Coast University Hospital (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
6000 - Perth - Royal Perth Hospital (2)
3052 - Parkville - Royal Children's Hospital Melbourne (2)
5042 - Bedford Park - Flinders Medical Centre (2)
2170 - Liverpool - Liverpool Hospital (2)
2109 - North Ryde - Macquarie University Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
NA
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
3149 - Mount Waverley - Waverley Private Hospital - Oncology (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
3168 - Clayton - Monash Children's Hospital (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
2031 - Randwick - Prince of Wales Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2487 - Cudgen - Tweed Valley Hospital (1)
2605 - Garran - The Canberra Hospital (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3066 - Epping - Northern Hospital (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
7000 - Hobart - Royal Hobart Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Lymphoma
B-cell lymphoma
B-cell malignancy
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Sarcoma
Leukaemia
Lymphoid leukaemia
Neurological cancer
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
Central nervous system cancer
Glioma
Malignant glioma
Rhabdomyosarcoma
Soft tissue sarcoma
Bladder cancer
Urogenital cancer
Mantle cell lymphoma
Cervical cancer
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Viral-related cancer
Breast adenocarcinoma
Breast cancer
HER2-positive breast cancer
Low-grade glioma
Anaplastic astrocytoma
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Glioblastoma
H3K27M-mutant glioma
High-grade glioma
Retinoblastoma
Alveolar rhabdomyosarcoma
Embryonal rhabdomyosarcoma
Sclerosing rhabdomyosarcoma
Neuroblastic tumour
Neuroblastoma
Peripheral nervous system tumour
Acute lymphoblastic leukaemia
B-cell acute lymphoblastic leukaemia/lymphoma
Mixed phenotype acute leukaemia
Bone cancer
Ewing family of tumours
Ewing sarcoma
Primitive neuroectodermal tumour
Head and neck cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy